Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.42 - $3.45
Previous CloseN/A
Volume22.63K
Average Volume (3M)308.00K
Market Cap
$30.21M
Enterprise Value$27.98M
Total Cash (Recent Filing)$26.30M
Total Debt (Recent Filing)$14.76M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 08, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding71,075,005
10 Day Avg. Volume254,049
30 Day Avg. Volume308,005
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)53.38
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.44
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$3.50Price Target Upside733.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPreclinical studies have shown a lack of accumulation in the retina, a key differentiator from previously approved GABA-AT inhibitor vigabatrin.
Drug EfficacyOV350 exhibits 100-1,000-fold higher potency for KCC2 compared to other inhibitors, limiting peripheral side effects.
Financial PerformanceOVID reported a significant decrease in R&D expenses, highlighting a 38% reduction quarter over quarter.
Bears Say
Clinical TrialsThe company plans to have a discussion with regulators about adding additional cohorts to the P1 study to explore broader dosing.
Regulatory ChallengesThe initiation of the Phase 2 proof-of-concept study of OV888 was paused to evaluate clinical design learnings from competitor programs.
---
Ownership Overview
9.63% Insiders
7.81% Mutual Funds
43.39% Other Institutional Investors
31.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.42 and its highest was $3.45 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $30.21M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 45 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Mar 11, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.169 by $0.039.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.14.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 71,075,005 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.169. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
---
Ovid Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (733.33% Upside)
$3.50 (733.33% Upside)
Blogger Sentiment
Neutral
OVID Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $5.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.06%
12-Months-Change
Fundamentals
Return on Equity
-33.88%
Trailing 12-Months
Asset Growth
-36.01%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
---
OVID Stock 12 Month Forecast
Average Price Target
$3.50
▲(733.33% Upside)
Technical Analysis
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Editas Medicine
―
Arvinas Holding Company
―
Boundless Bio Inc.
―
Best Analysts Covering OVID
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+40.94%
reiterated a buy rating 4 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +40.94% per trade.
---